Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024

June 5, 2024

https://www.globenewswire.com/news-release/2024/06/05/2893808/16259/en/Assembly-Biosciences-Presents-New-Data-Highlighting-Hepatitis-D-Virus-Entry-Inhibitor-ABI-6250-at-the-EASL-Congress-2024.html

— Poster highlights promising preclinical profile of ABI-6250 ahead of entry into the clinic, expected by end of 2024 —

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced new data for ABI-6250, the company’s orally bioavailable, small molecule hepatitis D virus (HDV) entry inhibitor candidate, featured in a poster presentation at the European Association for the Study of the Liver (EASL) Congress™, taking place June 5-8, 2024, in Milan, Italy.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.